公司資料
Senti Biosciences 股價、新聞與催化劑
- 股票代碼:
- SNTI
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.39 USD (-10.87%)
收盤價
最後更新: 2026年8月21日
30.6M USD
市值
股價為何變動
As of Aug 21, 2026, SNTI closed down 10.9% at $0.3886. No new same-company headline was identified in the current news window.
公司概覽
Gene Circuit Cell Therapy Company
Senti Biosciences uses a proprietary Gene Circuit platform to develop next-generation cell and gene therapies. Its logic-gated designs are intended to increase selective tumor-cell killing while protecting healthy tissue.
SENTI-202 Logic-Gated CAR-NK
SENTI-202 is an off-the-shelf CAR-NK candidate designed to target hematologic malignancies expressing CD33 and/or FLT3 while using an EMCN NOT gate to protect healthy hematopoietic stem and progenitor cells. An IL-15 release module is intended to improve CAR-NK persistence, expansion, and activity.
Registrational Path in AML
Senti Bio completed a Type B Initial Comprehensive Multidisciplinary RMAT meeting with the FDA and aligned on pivotal clinical and CMC strategy for SENTI-202. FDA feedback supports the potential use of a single-arm, multicenter pivotal trial in relapsed or refractory AML.
Allogeneic Manufacturing Strategy
SENTI-202 is being developed as an off-the-shelf product manufactured from selected donor material. Senti’s Donor X strategy is intended to improve consistency in potency, expansion, and clinical activity across production campaigns.
Logic-Gate Architecture
The OR gate enables recognition of either CD33 or FLT3 on malignant cells, while the EMCN NOT gate is intended to protect healthy hematopoietic cells. This combination illustrates how Senti’s Gene Circuit platform integrates multiple biological signals into a single cell therapy.
未來催化劑
- SENTI-202 is expected to advance into a single-arm, multicenter pivotal trial in relapsed or refractory AML to support potential registration.
- More complete Phase 1 data, particularly efficacy and MRD-negative responses under the Donor X manufacturing strategy, will inform execution of the pivotal program.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。